公开(公告)号：US12084424B2

公开(公告)日：2024-09-10

申请号：US18319630

申请日：2023-05-18

申请人： NOVARTIS AG

发明人： Luigi Franchi ,  Shomir Ghosh ,  Gary Glick ,  Jason Katz ,  Anthony William Opipari, Jr. ,  William Roush ,  Hans Martin Seidel ,  Dong-Ming Shen ,  Shankar Venkatraman ,  David Guenther Winkler

IPC分类号： C07D277/36 ,  C07C307/06 ,  C07D215/36 ,  C07D231/18 ,  C07D239/26 ,  C07D263/46 ,  C07D307/64 ,  C07D307/79 ,  C07D317/62 ,  C07D333/34 ,  C07D487/04 ,  C07C335/42 ,  C07D213/71 ,  C07D231/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D471/04

CPC分类号： C07D277/36 ,  C07C307/06 ,  C07D215/36 ,  C07D231/18 ,  C07D239/26 ,  C07D263/46 ,  C07D307/64 ,  C07D307/79 ,  C07D317/62 ,  C07D333/34 ,  C07D487/04 ,  C07C335/42 ,  C07D213/71 ,  C07D231/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D471/04

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:






or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US11718631B2

公开(公告)日：2023-08-08

申请号：US16756358

申请日：2018-10-12

申请人： Novartis AG

发明人： Shankar Venkatraman ,  Shomir Ghosh ,  William R. Roush ,  Dong-Ming Shen ,  Jason Katz ,  Hans Martin Seidel

IPC分类号： C07D498/04 ,  C07C311/51 ,  C07D231/12 ,  C07D317/46 ,  C07D209/04 ,  C07D215/14 ,  C07D307/54 ,  C07D471/04 ,  C07D487/04 ,  C07D409/12 ,  C07D277/30

CPC分类号： C07D498/04 ,  C07C311/51 ,  C07D209/04 ,  C07D215/14 ,  C07D231/12 ,  C07D277/30 ,  C07D307/54 ,  C07D317/46 ,  C07D409/12 ,  C07D471/04 ,  C07D487/04

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3

公开(公告)号：US11203579B2

公开(公告)日：2021-12-21

申请号：US16632849

申请日：2018-07-23

申请人： Novartis AG

发明人： Luigi Franchi ,  Shomir Ghosh ,  Gary Glick ,  Jason Katz ,  Anthony William Opipari, Jr. ,  William Roush ,  Hans Martin Seidel ,  Dong-Ming Shen ,  Shankar Venkatraman ,  David Guenther Winkler

IPC分类号： C07D277/36 ,  C07D307/64 ,  C07D333/34 ,  C07C307/06 ,  C07D215/36 ,  C07D231/18 ,  C07D239/26 ,  C07D263/46 ,  C07D307/79 ,  C07D317/62 ,  C07D487/04 ,  C07C335/42 ,  C07D213/71 ,  C07D231/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D471/04

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

公开(公告)号：US11724992B2

公开(公告)日：2023-08-15

申请号：US17496375

申请日：2021-10-07

申请人： Novartis AG

发明人： Luigi Franchi ,  Shomir Ghosh ,  Gary Glick ,  Jason Katz ,  Anthony William Opipari, Jr. ,  William Roush ,  Hans Martin Seidel ,  Dong-Ming Shen ,  Shankar Venkatraman ,  David Guenther Winkler

IPC分类号： C07D277/36 ,  C07D215/36 ,  C07D231/18 ,  C07D239/26 ,  C07D263/46 ,  C07D307/64 ,  C07D333/34 ,  C07C307/06 ,  C07D307/79 ,  C07D317/62 ,  C07D487/04 ,  C07C335/42 ,  C07D213/71 ,  C07D231/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D471/04

CPC分类号： C07D277/36 ,  C07C307/06 ,  C07D215/36 ,  C07D231/18 ,  C07D239/26 ,  C07D263/46 ,  C07D307/64 ,  C07D307/79 ,  C07D317/62 ,  C07D333/34 ,  C07D487/04 ,  C07C335/42 ,  C07D213/71 ,  C07D231/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D471/04

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:






or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US11597706B2

公开(公告)日：2023-03-07

申请号：US16094491

申请日：2017-04-18

申请人： Novartis AG

发明人： Gary Glick ,  Shomir Ghosh ,  William R. Roush

IPC分类号： C07C317/22 ,  C07D295/096 ,  C07D213/34 ,  C07D263/46 ,  C07D333/34 ,  C07D405/12 ,  C07D417/12 ,  C07D307/64 ,  C07D311/54 ,  C07D213/71 ,  C07D277/36

摘要： In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured: Formulae (I) and (II), wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.

公开(公告)号：US11447460B2

公开(公告)日：2022-09-20

申请号：US16094487

申请日：2017-04-18

申请人： Novartis AG

发明人： Gary Glick ,  Shomir Ghosh ,  William R. Roush ,  Dong-Ming Shen

IPC分类号： C07D333/34 ,  C07D215/36 ,  C07D265/30 ,  C07D213/28 ,  C07D307/64 ,  C07D231/44 ,  C07D277/34 ,  C07D307/82 ,  C07C381/00 ,  C07C311/29 ,  C07C317/14 ,  C07C311/37 ,  C07C311/51 ,  C07D231/18 ,  C07D277/36

摘要： In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US11339136B2

公开(公告)日：2022-05-24

申请号：US16094499

申请日：2017-04-18

申请人： Novartis AG

发明人： Gary Glick ,  Shomir Ghosh ,  William R. Roush

IPC分类号： C07D263/46 ,  C07D333/34 ,  C07D405/12 ,  C07D417/12 ,  C07D295/096 ,  C07D213/34 ,  C07D307/64 ,  C07D311/54 ,  C07D213/71 ,  C07D277/36 ,  C07C317/22

摘要： In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.

公开(公告)号：US11760735B2

公开(公告)日：2023-09-19

申请号：US17711205

申请日：2022-04-01

申请人： Novartis AG

发明人： Gary Glick ,  Shomir Ghosh ,  William R. Roush

IPC分类号： C07D263/46 ,  A61K31/41 ,  C07D333/34 ,  C07D405/12 ,  C07D417/12 ,  C07D295/096 ,  C07D213/34 ,  C07D307/64 ,  C07D311/54 ,  C07D213/71 ,  C07D277/36 ,  C07C317/22

CPC分类号： C07D263/46 ,  A61K31/41 ,  C07C317/22 ,  C07D213/34 ,  C07D213/71 ,  C07D277/36 ,  C07D295/096 ,  C07D307/64 ,  C07D311/54 ,  C07D333/34 ,  C07D405/12 ,  C07D417/12 ,  C07C2603/10

摘要： In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.

公开(公告)号：US11370763B2

公开(公告)日：2022-06-28

申请号：US16632850

申请日：2018-07-23

申请人： Novartis AG

发明人： Luigi Franchi ,  Shomir Ghosh ,  Gary Glick ,  Jason Katz ,  Anthony William Opipari, Jr. ,  William Roush ,  Hans Martin Seidel ,  Dong-Ming Shen ,  Shankar Venkatraman ,  David Guenther Winkler

IPC分类号： C07D265/30 ,  A61P1/00 ,  A61P11/00 ,  A61P19/08 ,  A61P35/00 ,  C07C381/10 ,  C07D209/26 ,  C07D211/78 ,  C07D215/06 ,  C07D231/12 ,  C07D239/26 ,  C07D239/36 ,  C07D261/08 ,  C07D263/46 ,  C07D277/36 ,  C07D317/50 ,  C07D333/34 ,  C07D401/12 ,  C07D409/12 ,  C07D417/12 ,  A61K45/06

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.